Time filter

Source Type

Kupershmidt L.,Rappaport Family Research Institute Technion | Amit T.,Rappaport Family Research Institute Technion | Bar-Am O.,Rappaport Family Research Institute Technion | Youdim M.B.H.,Rappaport Family Research Institute Technion | Weinreb O.,Rappaport Family Research Institute Technion
Mechanisms of Ageing and Development | Year: 2012

Based on a multimodal drug design paradigm, we have synthesized a multifunctional non-toxic, brain permeable iron chelating compound, M30, possessing the neuroprotective N-propargyl moiety of the anti-Parkinsonian drug, monoamine oxidase (MAO)-B inhibitor, rasagiline and the antioxidant-iron chelator moiety of an 8-hydroxyquinoline derivative of the iron chelator, VK28. Here, we report that a chronic systemic treatment of aged mice with M30 (1 and 5. mg/kg; 4 times weekly for 6 months), had a significant positive impact on neuropsychiatry functions and cognitive age-related impairment. M30 significantly reduced cerebral iron accumulation as demonstrated by Perl's staining, accompanied by a marked decrease in cerebral β-amyloid plaques. In addition, our results demonstrate that M30 caused a significant inhibition of both MAO-A and -B activities in the cerebellum of aged mice, compared with vehicle-treated aged control mice. In summary, the present study indicates that the novel MAO inhibitor/iron chelating drug, M30, acting against multiple brain targets could reverse age-associated memory impairment and provide a potential treatment against the progression of neurodegeneration in ageing. © 2012 Elsevier Ireland Ltd.

Loading Rappaport Family Research Institute Technion collaborators
Loading Rappaport Family Research Institute Technion collaborators